#pharmaceutical

बायोफार्मा कंपन्या अनुसूचित राष्ट्रीय औषध मूल्य नियमांचा आपला संपर्क कमी करण्यासाठी आंतरराष्ट्रीय लायसेन्सिंग करार पुनर्रचना करत आहेत, जे अमेरिकन औषध किंमता इतर देशात मिळाल्या सर्वात कमी किंमतीशी जोडतात.

Ugur Sahin and Ozlem Tureci will exit BioNTech by year-end to start a company focused on next-generation mRNA innovations.

Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.